Cassava Sciences licenses simufilam method of treatment patent

Cassava Sciences (SAVA) has entered into an agreement with Yale University for a license to intellectual property rights, including an exclusive license to an issued US method of treatment patent for simufilam as a potential treatment for seizures related to rare neurodevelopmental disorders including tuberous sclerosis complex. Simufilam is Cassava’s proprietary small molecule drug candidate that targets filamin A.